Overview
Tirzepatide (Mounjaro, Zepbound) is a dual agonist that activates both the GIP and GLP-1 receptors. It is FDA-approved and prescription-available, and has shown notable results in weight-management trials.
How It's Thought to Work
By activating both GIP and GLP-1 receptors, tirzepatide influences insulin secretion, appetite, and gastric emptying, with effects that trials suggest may exceed GLP-1 agonism alone.
What the Research Says
Backed by the SURPASS (diabetes) and SURMOUNT (obesity) human clinical trial programs — large, randomized, and peer-reviewed.
Regulatory & Legal Status
FDA-approved and prescription-only. Compounded and gray-market versions raise safety and quality concerns.
Safety Considerations
GI side effects are common; contraindications and warnings apply. Use only under a prescribing clinician.